Keywords

cough, dyspnea, idiopathic pulmonary fibrosis, nintedanib, pirfenidone, respiratory function tests

 

Authors

  1. Vega-Olivo, Michelle CRNP
  2. Criner, Gerard J. MD

Abstract

Abstract: Idiopathic pulmonary fibrosis (IPF) is a rare disease characterized by decline in lung function, dyspnea, and cough. The clinical course of IPF is variable and unpredictable. Early referral to specialists is key to ensure timely and accurate diagnosis. Two antifibrotic drugs (nintedanib and pirfenidone) have been approved for the treatment of IPF.